Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

NCT00306566 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Cytos Biotechnology AG